These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35738428)

  • 1. Learning About Allosteric Drugs and Ways to Design Them.
    Wah Tan Z; Tee WV; Berezovsky IN
    J Mol Biol; 2022 Sep; 434(17):167692. PubMed ID: 35738428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions.
    Tee WV; Lim SJM; Berezovsky IN
    J Med Chem; 2024 Oct; 67(19):17191-17206. PubMed ID: 39326868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response.
    Tee WV; Guarnera E; Berezovsky IN
    PLoS Comput Biol; 2018 Jun; 14(6):e1006228. PubMed ID: 29912863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric drugs: New principles and design approaches.
    Tee WV; Berezovsky IN
    Curr Opin Struct Biol; 2024 Feb; 84():102758. PubMed ID: 38171188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of hidden allosteric sites as novel targets for allosteric drug design.
    Lu S; Ji M; Ni D; Zhang J
    Drug Discov Today; 2018 Feb; 23(2):359-365. PubMed ID: 29030241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting protein flexibility to predict the location of allosteric sites.
    Panjkovich A; Daura X
    BMC Bioinformatics; 2012 Oct; 13():273. PubMed ID: 23095452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric drugs and mutations: chances, challenges, and necessity.
    Guarnera E; Berezovsky IN
    Curr Opin Struct Biol; 2020 Jun; 62():149-157. PubMed ID: 32062398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of dualsteric GPCR ligands: quests and promise.
    Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
    Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward Comprehensive Allosteric Control over Protein Activity.
    Guarnera E; Berezovsky IN
    Structure; 2019 May; 27(5):866-878.e1. PubMed ID: 30827842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric small molecule modulators of nuclear receptors.
    Meijer FA; Leijten-van de Gevel IA; de Vries RMJM; Brunsveld L
    Mol Cell Endocrinol; 2019 Apr; 485():20-34. PubMed ID: 30703487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificities of Protein Homology Modeling for Allosteric Drug Design.
    Jakowiecki J; Orzeł U; Gliździnska A; Możajew M; Filipek S
    Methods Mol Biol; 2023; 2627():339-348. PubMed ID: 36959457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design.
    Huang W; Nussinov R; Zhang J
    Methods Mol Biol; 2017; 1529():439-446. PubMed ID: 27914066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmasking allosteric-binding sites: novel targets for GPCR drug discovery.
    Casadó-Anguera V; Casadó V
    Expert Opin Drug Discov; 2022 Aug; 17(8):897-923. PubMed ID: 35649692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.
    Fronik P; Gaiser BI; Sejer Pedersen D
    J Med Chem; 2017 May; 60(10):4126-4134. PubMed ID: 28140580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs.
    Bartuzi D; Kaczor AA; Matosiuk D
    Methods Mol Biol; 2018; 1705():297-319. PubMed ID: 29188568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single Binding Pockets Versus Allosteric Binding.
    Song K; Zhang J
    Methods Mol Biol; 2018; 1825():295-326. PubMed ID: 30334210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of G protein-coupled receptors.
    May LT; Leach K; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2007; 47():1-51. PubMed ID: 17009927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of protein allostery in rational anticancer drug design: an update.
    Nussinov R; Jang H
    Expert Opin Drug Discov; 2024 Sep; 19(9):1071-1085. PubMed ID: 39068599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance.
    Ni D; Li Y; Qiu Y; Pu J; Lu S; Zhang J
    Trends Pharmacol Sci; 2020 May; 41(5):336-348. PubMed ID: 32171554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery.
    Persechino M; Hedderich JB; Kolb P; Hilger D
    Pharmacol Ther; 2022 Sep; 237():108242. PubMed ID: 35863587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.